A new report by global brokerage firm Bernstein states that artificial intelligence adoption could boost Indian pharmaceutical profit margins by 3 to 4 percentage points by 2035. Driven by AI efficiencies in R&D and manufacturing, the domestic biopharma sector is projected to reach a $195 billion valuation over the next decade.
MUMBAI, June 16, 2026 — Artificial intelligence (AI) adoption could add 3 to 4 percentage points to the profit margins of Indian pharmaceutical companies by 2035, according to a comprehensive sector research report released by global brokerage firm Bernstein. The projected profitability boost comes as domestic life sciences enterprises accelerate the integration of predictive algorithms and automated enterprise systems across core operational workflows.
The detailed research note initiates structural coverage on the Indian healthcare ecosystem with a highly positive outlook. Bernstein argues that the country's biopharma market is entering an "Innovation Power Decade," on track to grow fourfold to reach an estimated valuation of $195 billion over the next ten years.
R&D and Manufacturing to Drive 70% of Profitability Gains
According to Bernstein’s proprietary adoption models, the enterprise-wide rollout of artificial intelligence will fundamentally transform traditional cost structures. The brokerage estimates that research and development (R&D) optimization alongside advanced manufacturing operations will account for nearly 70 percent of the total AI-driven margin expansion.
In traditional laboratories, machine learning models drastically shorten the multi-year timelines required to optimize molecules, predict compound toxicities, and manage early-stage clinical trial cohorts.
On the factory floor, the transition to "Agentic AI" allows manufacturers to run real-time predictive maintenance cycles on heavy equipment, minimize raw material waste, and optimize automated high-throughput production lines. This systematic drop in operational friction directly pads the bottom line, offering a vital cushion against persistent global inflation and raw material pricing shocks.
"Rainmakers" Over New Molecule Discovery
A core pillar of Bernstein’s investment thesis is that Indian biopharma should avoid trying to replicate the high-risk, multi-billion-dollar new molecular entity (NME) discovery framework favored by Western multinational conglomerates. Instead, the report advises domestic operators to lean heavily into specialty medicines, niche therapies, and incremental innovation.
As detailed above, Bernstein identifies six highly lucrative innovation "rainmakers" capable of adding an aggregate $70 billion to $75 billion to the total industry size without demanding excessive, speculative capital burn. This calculated approach allows companies to climb the value chain by creating complex generics and bio-better treatments.
Furthermore, Bernstein highlights that Indian biopharma is rapidly building an improved quality culture, positioning the domestic sector to command the largest network of future-ready, compliant manufacturing plants globally over the coming decade.
Stock Specifics and Market Impact
The structural upgrade has triggered immediate revisions to institutional investment strategies targeting listed Indian healthcare entities. In its coverage launch, Bernstein designated Zydus Lifesciences as its top investment pick within the sector, giving it an Outperform rating due to its strong R&D pipeline and robust operational readiness.
The brokerage also assigned Outperform ratings to large-cap operators Lupin and Sun Pharmaceutical Industries, citing attractive historical valuations that currently trade well below their ten-year averages. Conversely, the report presented non-consensus Underperform ratings for Mankind Pharma and Biocon, while anchoring Aurobindo Pharma with a neutral Market-Perform grade.
According to Bernstein's financial analysts, current public equities pricing fails to capture the long-term margin expansions that will be unlocked as these corporate portfolios shift away from low-margin commodity generics.
Official Sources Section
The underlying fiscal metrics, sector evaluations, and corporate ratings track directly with published institutional reporting:
Macroeconomic market sizes and adoption modeling statistics are derived from the official India Healthcare Strategy Note distributed via the global research division of Bernstein Research.
Historical equity valuations, multi-year multiple averages, and statutory financial data are mapped directly against corporate listings on the BSE Limited.
Quote Section
"According to officials familiar with the sector's digital transition, Gen AI adoption in Indian biopharma is rapidly shifting from basic administrative automation to deep innovation efficiency," the Bernstein report stated. "Organizers stated that incremental innovation across specialized niches will act as the premier earnings catalyst for the industry through the next decade."
Why It Matters
For retail investors and industry workers, Bernstein's analysis indicates that the long-standing image of India as merely the "world's generic pharmacy" is coming to an end. Embracing enterprise-wide AI tools directly impacts corporate financial stability, allowing domestic firms to maintain strong profit margins even when facing strict price controls at home and competitive pricing pressures in the United States generic market.
Key Facts at a Glance
Margin Expansion Target: Expected to contribute an additional 3 to 4 percentage points to corporate bottom lines by 2035.
Sector Valuation Projection: The Indian biopharma ecosystem is modeled to expand fourfold, hitting $195 billion by 2035.
Primary Profit Drivers: Laboratory R&D and factory manufacturing upgrades will generate 70 percent of the total efficiency gains.
Top Pick Selection: Zydus Lifesciences stands as the brokerage's preferred equity asset based on innovation capability.
Frequently Asked Questions
How exactly does AI help a pharmaceutical company save money on manufacturing?
AI systems use real-time data from factory sensors to predict exactly when a machine will fail, preventing costly unscheduled shutdowns. It also automates complex quality control inspections, lowering batch failure rates and reducing raw material waste.
What is the difference between new molecule discovery and incremental innovation?
New molecule discovery involves creating an entirely new chemical structure from scratch, which can take over a decade and cost billions with a high risk of failure. Incremental innovation takes existing, proven drugs and improves them—such as making them extended-release or combining them with a specialized injection device.
Why are current market valuations for Indian pharma stocks considered underpriced by Bernstein?
The brokerage points out that stock market models often evaluate Indian pharmaceutical companies based on their legacy, low-margin generic drug portfolios. They fail to accurately price in the major margin improvements and revenues coming down the line from AI adoption and specialized specialty therapies.
Source: Bernstein Institutional Research Database, BSE India Corporate Filing Repository
